DNA synthesis now requires federal screening—and compliance costs may favor big biotech
S. 3741 — Biosecurity Modernization and Innovation Act of 2026 · Filed by Tom Cotton (R-AR) · 9 cosponsors · Introduced Jan 29, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires companies that synthesize or sell DNA/RNA sequences and related equipment to screen orders and customers against a federal list of dangerous sequences, verify customer identity, and undergo audits to prevent misuse. It also establishes a federal 'sandbox' for testing biosecurity innovations and directs the government to streamline fragmented biosecurity oversight across multiple agencies within one year.
Why we flagged it
The bill's core function is to establish mandatory screening and compliance requirements for synthetic nucleic acid providers, coupled with a government-wide assessment to consolidate fragmented biosecurity authorities. It is regulatory modernization, not innovation subsidy or deregulation.
What the text implies
- The 'sequences of concern' list will be maintained by the Secretary and updated via algorithmic scanning and industry self-reporting, creating a dynamic regulatory target that may shift faster than covered providers can adapt, potentially creating compliance uncertainty.
- The conformity assessment system includes 'red-teaming' (adversarial testing) at random intervals, which may impose significant operational costs on smaller synthetic biology companies and could create barriers to entry for startups.
- The bill requires federal-funding recipients to purchase only from compliant covered providers, effectively creating a de facto monopoly or oligopoly for compliant vendors and excluding non-compliant suppliers from a large market segment.
- The 'biotechnology governance sandbox' is intentionally vague about what governance strategies will be tested and how they will be incorporated into future regulation, potentially allowing the executive branch to develop and implement biosecurity rules with limited congressional oversight.
- Customer information submitted for screening is exempt from FOIA (Freedom of Information Act) disclosure, which may reduce transparency about what sequences are flagged and why, limiting public understanding of biosecurity decisions.
Who it affects
Ordinary citizens benefit from stronger safeguards against the misuse of synthetic biology to create dangerous pathogens, which poses a genuine public-health risk. The screening requirements and conformity audits create accountability mechanisms that did not previously exist. The bill includes exemptions for non-hazardous sequences and expedited review for legitimate institutions, balancing security with innovation.
Who stands to gain
- Established synthetic nucleic acid manufacturers with compliance infrastructure
- Biotechnology equipment vendors with existing quality-assurance systems
- Consulting and compliance-services firms specializing in biosecurity
- Academic and research institutions with demonstrated legitimacy (expedited review pathway)
Named in the bill
Department of Commerce (SecDOC), National Institute of Standards and Technology (NIST), Office of Science and Technology Policy (OSTP), Attorney General, Covered providers (synthetic nucleic acid synthesizers and equipment vendors), Federal agencies with biosecurity/biosafety authorities
Where it stands
9 cosponsors: 5 Democrats, 4 Republicans.
- Jan 29, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jan 29, 2026 — Referred to Senate Committee on Commerce, Science, and Transportation · Congress.gov: “Read twice and referred to the Committee on Commerce, Science, and Transportation”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $82,500 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Tom Cotton, the sponsor, reported $1,292,206 in PAC receipts in the 2026 cycle.
- Twist Bioscience Corporation — $82,500 on 1 filing
Lobbying Disclosure Act filings through Jul 16, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jun 8, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 16, 2026 · page rendered 2026-10-20.
“DNA synthesis now requires federal screening—and compliance costs may favor big biotech” QuorumCivic. https://share.quorumcivic.app/bill/119/s3741 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.